Login / Signup

Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.

Wolfram E SamlowskiMichelle A SilverAndriana HohlbauchShujing ZhangEmilie ScherrerMizuho Fukunaga-KalabisClemens KreplerRuixuan Jiang
Published in: Future oncology (London, England) (2022)
Aim: To describe clinical outcomes after complete surgical resection of stage IIB and IIC melanoma. Methods: Adult patients (n = 567) with stage IIB or IIC cutaneous melanoma initially diagnosed and completely resected from 2008-2017 were identified using data from a US community-based oncology network. Results: Median patient follow-up was 38.8 months from melanoma resection to death, last visit or data cutoff (31 December 2020). For stage IIB (n = 375; 66%), Kaplan-Meier median real-world recurrence-free survival (rwRFS) was 58.6 months (95% CI, 48.6-69.5). For stage IIC (n = 192; 34%), median rwRFS was 29.9 months (24.9-45.5). Overall, 44% of patients had melanoma recurrence or died; 30% developed distant metastases. Conclusion: Melanoma recurrence was common, highlighting the need for effective adjuvant therapy for stage IIB and IIC melanoma.
Keyphrases
  • free survival
  • skin cancer
  • healthcare
  • end stage renal disease
  • basal cell carcinoma
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction
  • early stage
  • prognostic factors
  • big data
  • data analysis